Technological Advancements and Increasing Adoption of Minimally Invasive Procedures to Drive the Cardiovascular Devices Market to USD 142,666.1 Million by 2033, at a CAGR of 9.1% – Coherent Market Insights
The Cardiovascular Devices Market, estimated at USD 71,240.8 Mn in 2026, is expected to exhibit a CAGR of 9.1% and reach USD 1,42,666.1 Mn by 2033.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Market Statistics
The Global Cardiovascular Devices Market is estimated to account for USD 71,240.8 Mn in terms of value by the end of 2026.
-
Drivers
Increase in demand for cardiovascular devices across the globe is expected to drive growth of the global cardiovascular devices market during the forecast period. For instance, the rising burden of cardiovascular diseases across the globe is increasing or has increased demand for cardiovascular diagnostics and treatment devices. In September 2025, GE Healthcare announced the launch of its first ‘Made in India’, ‘Artificial Intelligence (AI)-powered’ Cath lab - Optima IGS 320 to advance cardiac care in India. The new generation of interventional imaging software in Optima enables clinical versatility to guide non-invasive procedures with greater precision. It also helps reduce the burden on interventionalists and may increase their attention on the procedure.
-
Opportunities
High prevalence of cardiovascular diseases and rising geriatric population worldwide is expected to provide significant growth opportunities for players in the global cardiovascular devices market. Increasing rates of cardiovascular disease necessitate continuous monitoring. The development of cardiovascular devices has allowed for real-time patient monitoring and diagnosis. Heart disease is the leading cause of death in the U.S. According to the American Heart Association, in 2025, over 19.1 million deaths were attributed to CVD globally. The highest mortality rates attributable to CVD in 2025 were in Eastern Europe and Central Asia, with higher levels also seen in North Africa and the Middle East, Central Europe, sub-Saharan Africa, and South and Southeast Asia.
-
Restraints
Stringent regulatory policies, product recalls, and high cost of cardiovascular devices and cardiac procedures are expected to hamper growth of the global cardiovascular devices market during the forecast period. For instance, the complications and additional surgical procedures associated with cardiac surgeries increase the overall cost of a cardiovascular procedure as well as cardiovascular devices. The high-cost cardiovascular stents with prices ranging from US$ 300-450 for each stent, makes it difficult to afford. However, average cost of heart procedures is less in low- and middle-income countries, as compared to developed countries. The majority of cardiovascular devices are regulated as medical devices in an independent sub-category.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cardiovascular-devices-market-5526
Key Takeaways
The global cardiovascular devices market was valued at USD 71,240.8 Mn in 2026 and is forecast to reach a value of USD 1,42,666.1 Mn by 2033 at a CAGR of 9.1% between 2026 and 2033.
Among device type, therapeutic and surgical devices segment held dominant position in the global cardiovascular devices market in 2026, accounting for 80.6% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends
Increase in focus on disease diagnosis and rise in use of electrocardiograms (ECGs) is one of the key trends expected to boost the growth of the global biosurgery market. Due to rise in burden of cardiovascular diseases, demand for early diagnosis is also increasing, which in turn has increased the demand for cardiovascular devices worldwide. More people are using ECGs for diagnostic and monitoring purposes and are especially popular in the home healthcare market. Moreover, market players are focusing on developing or launching wearable ECG monitors to capture ECG and heart rate. This trend is also expected to continue during the forecast period.
Competitive Landscape
Major players operating in the global cardiovascular devices market include Livanova PLC, B. Braun Melsungen AG, Edwards Lifesciences, Biotronik, Medtronic PLC, GE Healthcare, Cardinal Health Inc., Abbott Laboratories, Siemens Healthineers AG, WL Gore & Associates Inc., Boston Scientific Corporation, and Canon Medical Systems Corporation.
Recent Developments
- In June 2026, Octane launched the Mussallem Cardiovascular Accelerator, a 14-week virtual program supporting startups developing technologies for cardiovascular disease diagnosis, treatment, monitoring, and patient care. Selected companies will receive mentoring, commercialization guidance, investor-readiness support, and introductions to clinicians, operators, investors, and strategic partners. Participants will also showcase their innovations at Octane’s Cardiovascular Tech Forum, helping accelerate funding, market entry, and clinical impact across cardiovascular care in the United States.
- In May 2026, Abbott, a global healthcare company launched the TriClip transcatheter edge-to-edge repair system in India for treating tricuspid regurgitation. The minimally invasive device is delivered through a leg vein and repairs the tricuspid valve without open-heart surgery. (Source: Abbott)
- On April 21, 2026, Johnson & Johnson introduced the CARTOSOUND SONATA Module for electrophysiology procedures. The AI-powered technology automatically converts intracardiac ultrasound images into detailed heart maps and labels cardiac structures, supporting the treatment of atrial fibrillation and other arrhythmias.
- In April 2026, Conavi Medical, Medical group in Toronto, Canada received FDA 510(k) clearance for its next-generation intravascular imaging system. The platform combines intravascular ultrasound and optical coherence tomography, providing simultaneous views of deep vessel structures and high-resolution surface details during coronary interventions.
- In June 2025, Medtronic PLC announced the launch of Micra AV, a miniaturized, self-contained pacemaker that delivers advanced pacing technology to the atrioventricular (AV) block patients, via a minimally invasive approach.
- In January 2025, Boston Scientific acquired wearable cardiac sensor maker, Preventice Solutions, the maker of various wearable cardiac sensors for remote patient monitoring.
- In September 2025, Fitbit received the U.S. Food and Drug Association’s (FDA’s) approval, along with the CE mark, for the ECG app, to help identify cases of irregular heart rhythm.
- In February 2025, Abbott received CE Mark for the Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D). The devices have heart rhythm management capabilities, along with a new set of benefits for people in Europe with the abnormal heart rhythms and risk of heart failure.
Contact Us